바이오모아 (BioMoa) — ADC · Antibody

8428프로그램 40FDA 승인

42오늘 방문

1,522누적 방문

7303갱신 대기 S–CData Tier S/A/B차세대 →Insight 1032HER2 breast 4683Antibody 2713CGT →Psoriasis →NSCLC 40FDA 승인

피드 Data Tier 차세대 Insight

최근 활동

RSS →

CGTBiologicstaleNational Institutes of Health C…Phase 2

anti-p53 T-cell receptor-transduced peripheral blood lymphocytes (anti-p53 T-cell receptor-transduced peripheral blood lymphocytes)

Kidney Cancer; Melanoma (Skin) · Kidney Cancer

#KidneyCancer#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 DISCONTINUED

CGTBiologicstaleAMERICAN ORGAN TRANSPLANT AND C…Phase 2

Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney (Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney)

End-Stage Renal Disease; End Stage Renal Disease on Dialysis · End-Stage Renal Disease

#End-StageRenalDisease#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleAMERICAN ORGAN TRANSPLANT AND C…Phase 2

Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver (Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver)

Liver Diseases; Liver Cancer · Liver Diseases

#LiverDiseases#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

anti-gp100:154-162 Tcell receptor (TCR, anti-gp100:154-162 Tcell receptor, anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL))

Metastatic Melanoma; Skin Cancer · Metastatic Melanoma

#MetastaticMelanoma#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 DISCONTINUED

CGTBiologicstaleM.D. Anderson Cancer CenterPhase 1

NY-ESO-1 TCR/IL-15 NK (NY-ESO-1 TCR/IL-15 NK)

Synovial Sarcoma; Myxoid/Round Cell Liposarcoma · Synovial Sarcoma

#SynovialSarcoma#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine)

Prostate Specific Antigens; Prostate Neoplasms · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 ACTIVE

CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

MOv-gamma chimeric receptor gene (MOv-gamma chimeric receptor gene)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

AntibodystaleBeiGenePreclinical

tislelizumab, azacytidine, lenalidomide (tislelizumab, azacytidine, lenalidomide)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Preclinical#항체#면역항체+5

임상시험 1상태 ACTIVE

CGTBiologicstaleThe Affiliated Nanjing Drum Tow…Phase 2

Memory-Like NK Cells (Memory-Like NK Cells)

Advanced Solid Cancers · Advanced Solid Cancers

#AdvancedSolidCancers#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicM.D. Anderson Cancer Centervedotin (BV) and, in Hodgki…Phase 2

Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells (Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells)

Relapsed/Refractory Myeloma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 1상태 RECRUITING

CGTBiologicstaleUniversidad Autonoma de MadridPhase 2

T memory cells and NK cells (T memory cells and NK cells)

Corona Virus Infection · Corona Virus Infection

#CoronaVirusInfection#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

CGTBiologicstaleShanghai Simnova Biotechnology …Phase 1

CAR-NK-CD19 Cells (CAR-NK-CD19 Cells)

Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3

효능 ORR 0%임상시험 1상태 ACTIVE

CGTBiologicstaleChinese PLA General HospitalPhase 2

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T))

Non-hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleImugene LimitedPhase 1

Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody (Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma · PD-L1

#PD-L1#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

AntibodystaleMalaria Research and Training C…Phase 2

VRC-MALMAB0114-00-AB (L9LS, L9LS (VRC-MALMAB0114-00-AB))

Plasmodium Falciparum Infection; Malaria · Plasmodium Falciparum Infection

#PlasmodiumFalciparumInfection#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleIstituto Clinico HumanitasPhase 2

anti-NKG2A monoclonal antibody (Monalizumab, Monalizumab (anti-NKG2A monoclonal antibody))

Acute Myeloid Leukaemia; MDS (Myelodysplastic Syndrome) · Acute Myeloid Leukaemia

#AcuteMyeloidLeukaemia#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 RECRUITING

CGTBiologicstaleMemorial Sloan Kettering Cancer…Phase 1

cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8 (cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8)

Neuroblastoma; Bone Marrow, Sympathetic Nervous System · Neuroblastoma

#Neuroblastoma#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 ACTIVE

CGTBiologicstaleBeijing Bio-Targeting Therapeut…Phase 1

Novel oncolytic virus Ad-TD-nsIL12（BioTTT001） (Novel oncolytic virus Ad-TD-nsIL12（BioTTT001）)

High-grade Glioma · High-grade Glioma

#High-gradeGlioma#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstaleXiaorong WuPhase 2

Novel oncolytic virus Ad-TD-nsIL12 (Novel oncolytic virus Ad-TD-nsIL12)

Glioma · Glioma

#Glioma#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

CGTBiologicstaleIRCCS Azienda Ospedaliero-Unive…Preclinical

Alloreactive NK cell infusion (Alloreactive NK cell infusion)

Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia in Remissio

#AdultAcuteMyeloidLeukemiainRemis#CGT#Preclinical#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

AntibodystaleRochePhase 3

trastuzuamb (Herceptin, Herceptin (trastuzuamb))

HER2 Positive Early or Locally Advanced Breast Cancer · HER2

#HER2#Antibody#Phase3#항체#면역항체+3

효능 ORR 91.2%임상시험 1상태 ACTIVE

CGTBiologicstaleTianjin Medical University Seco…Preclinical

Programmed death receptor-1 inhibitor (Programmed death receptor-1 inhibitor)

Malignant Pleural Mesothelioma, Advanced · Malignant Pleural Mesothelioma, Advanced

#MalignantPleuralMesotheliomaAdva#CGT#Preclinical#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

AntibodystaleThe Affiliated Hospital of Qing…Phase 1

HS627 (recombinant monoclonal antibody against human epidermal growth factor receptor injection, recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627))

Healthy Volunteers · Healthy Volunteers

#HealthyVolunteers#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Lenvatinib plus Pembrolizumab)

Liver Neoplasm Malignant Primary; Cholangiocarcinoma · Liver Neoplasm Malignant Primary

#LiverNeoplasmMalignantPrimary#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleRochePhase 3

recombinant human thrombopoietin (rhTPO, recombinant human thrombopoietin, recombinant human thrombopoietin (rhTPO); rituximab)

Purpura; Idiopathic Thrombocytopenic Purpura · Purpura

#Purpura#Antibody#Phase3#항체#면역항체+3

임상시험 1상태 DISCONTINUED

139 / 142 페이지

← 이전 다음 →

전체 8,428개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 42 / 1,522

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

anti-p53 T-cell receptor-transduced peripheral blood lymphocytes (anti-p53 T-cell receptor-transduced peripheral blood lymphocytes)

Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney (Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney)

Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver (Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver)

anti-gp100:154-162 Tcell receptor (TCR, anti-gp100:154-162 Tcell receptor, anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL))

NY-ESO-1 TCR/IL-15 NK (NY-ESO-1 TCR/IL-15 NK)

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine)

MOv-gamma chimeric receptor gene (MOv-gamma chimeric receptor gene)

tislelizumab, azacytidine, lenalidomide (tislelizumab, azacytidine, lenalidomide)

Memory-Like NK Cells (Memory-Like NK Cells)

Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells (Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells)

T memory cells and NK cells (T memory cells and NK cells)

CAR-NK-CD19 Cells (CAR-NK-CD19 Cells)

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T))

Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody (Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody)

VRC-MALMAB0114-00-AB (L9LS, L9LS (VRC-MALMAB0114-00-AB))

anti-NKG2A monoclonal antibody (Monalizumab, Monalizumab (anti-NKG2A monoclonal antibody))

cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8 (cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8)

Novel oncolytic virus Ad-TD-nsIL12（BioTTT001） (Novel oncolytic virus Ad-TD-nsIL12（BioTTT001）)

Novel oncolytic virus Ad-TD-nsIL12 (Novel oncolytic virus Ad-TD-nsIL12)

Alloreactive NK cell infusion (Alloreactive NK cell infusion)

trastuzuamb (Herceptin, Herceptin (trastuzuamb))

Programmed death receptor-1 inhibitor (Programmed death receptor-1 inhibitor)

HS627 (recombinant monoclonal antibody against human epidermal growth factor receptor injection, recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627))

pembrolizumab (Keytruda, Lenvatinib plus Pembrolizumab)

recombinant human thrombopoietin (rhTPO, recombinant human thrombopoietin, recombinant human thrombopoietin (rhTPO); rituximab)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

anti-p53 T-cell receptor-transduced peripheral blood lymphocytes (anti-p53 T-cell receptor-transduced peripheral blood lymphocytes)

Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney (Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney)

Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver (Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver)

anti-gp100:154-162 Tcell receptor (TCR, anti-gp100:154-162 Tcell receptor, anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL))

NY-ESO-1 TCR/IL-15 NK (NY-ESO-1 TCR/IL-15 NK)

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine)

MOv-gamma chimeric receptor gene (MOv-gamma chimeric receptor gene)

tislelizumab, azacytidine, lenalidomide (tislelizumab, azacytidine, lenalidomide)

Memory-Like NK Cells (Memory-Like NK Cells)

Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells (Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells)

T memory cells and NK cells (T memory cells and NK cells)

CAR-NK-CD19 Cells (CAR-NK-CD19 Cells)

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T))

Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody (Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody)

VRC-MALMAB0114-00-AB (L9LS, L9LS (VRC-MALMAB0114-00-AB))

anti-NKG2A monoclonal antibody (Monalizumab, Monalizumab (anti-NKG2A monoclonal antibody))

cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8 (cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8)

Novel oncolytic virus Ad-TD-nsIL12（BioTTT001） (Novel oncolytic virus Ad-TD-nsIL12（BioTTT001）)

Novel oncolytic virus Ad-TD-nsIL12 (Novel oncolytic virus Ad-TD-nsIL12)

Alloreactive NK cell infusion (Alloreactive NK cell infusion)

trastuzuamb (Herceptin, Herceptin (trastuzuamb))

Programmed death receptor-1 inhibitor (Programmed death receptor-1 inhibitor)

HS627 (recombinant monoclonal antibody against human epidermal growth factor receptor injection, recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627))

pembrolizumab (Keytruda, Lenvatinib plus Pembrolizumab)

recombinant human thrombopoietin (rhTPO, recombinant human thrombopoietin, recombinant human thrombopoietin (rhTPO); rituximab)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

anti-p53 T-cell receptor-transduced peripheral blood lymphocytes (anti-p53 T-cell receptor-transduced peripheral blood lymphocytes)

Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney (Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney)

Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver (Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver)

anti-gp100:154-162 Tcell receptor (TCR, anti-gp100:154-162 Tcell receptor, anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL))

NY-ESO-1 TCR/IL-15 NK (NY-ESO-1 TCR/IL-15 NK)

T-cell receptor alternate reading frame protein (TARP, T-cell receptor alternate reading frame protein, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine)

MOv-gamma chimeric receptor gene (MOv-gamma chimeric receptor gene)

tislelizumab, azacytidine, lenalidomide (tislelizumab, azacytidine, lenalidomide)

Memory-Like NK Cells (Memory-Like NK Cells)

Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells (Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells)

T memory cells and NK cells (T memory cells and NK cells)

CAR-NK-CD19 Cells (CAR-NK-CD19 Cells)

TCR reserved and Power3 (SPPL3, TCR reserved and Power3, TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T))

Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody (Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody)

VRC-MALMAB0114-00-AB (L9LS, L9LS (VRC-MALMAB0114-00-AB))

anti-NKG2A monoclonal antibody (Monalizumab, Monalizumab (anti-NKG2A monoclonal antibody))